My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
June 2016
POLICY AND ADVOCACY
IDSA Continues to Drive Legislative Progress on Antimicrobial Resistance
IDSA and the Pew Charitable Trusts hosted a June 9 congressional briefing featuring IDSA Treasurer Helen Boucher, MD, FIDSA, and Lord Jim O’Neill, Chair of the UK Antimicrobial Resistance (AMR) Review. The briefing publicized the UK AMR Review’s final report (PDF), which echoed key IDSA recommendations for incentivizing antibiotic and diagnostics research and development (R&D); strengthening stewardship, surveillance and data collection in human and animal health; and investing in the ID workforce. 
 
Dr. Boucher highlighted the central role of ID physicians in combating resistance and IDSA legislative proposals to spur antibiotic and diagnostic R&D, including the Limited Population Antibacterial Drug (LPAD) bill to allow antibiotics for the most highly resistant pathogens to be studied in smaller clinical trials and approved only for the patients who need them most, and the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act to provide a tax credit for the most urgently needed new antibiotics and rapid diagnostics. You can support this effort by contacting your congressional representatives with a prepared IDSA message
 
The House Energy and Commerce Oversight and Investigations Subcommittee held a June 14 hearing on progress in the US response to antibiotic resistance, featuring updates from the Centers for Disease Control and Prevention (CDC), National Institutes of Allergy and Infectious Diseases (NIAID), Food and Drug Administration (FDA), and Biomedical Advanced Research and Development Authority (BARDA). IDSA also briefed (PDF) committee staff. 
 
The Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) held a June 21-22 meeting (PDF) to discuss incentives for antibiotics, diagnostics, vaccines and other therapeutics, as well as antibiotic resistance in agriculture and environmental health. IDSA submitted comments to PACCARB (PDF) and the Administration (PDF). IDSA Past President Martin Blaser, MD, FIDSA, chairs the PACCARB, and other IDSA members serving on the PACCARB include Dr. Boucher, Angela Caliendo, MD, FIDSA; Sara Cosgrove, MD, FIDSA and Robert Weinstein, MD, FIDSA.


< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
FDA Alerts Health Facilities of M. Chimaera Due to Heater-cooler devices; CDC Continued Updates on Zika Testing
Guidelines Survey: Please Take 10 Minutes to Share Your Feedback
CLINICAL PRACTICE MANAGEMENT
Antimicrobial Stewardship Programs via Telehealth
IDSA Webinar Explains CMSís Proposed New Payment Program
POLICY AND ADVOCACY
IDSA Continues to Drive Legislative Progress on Antimicrobial Resistance
Zika Funding Remains in Limbo
Senate Bill Would Increase Funding for Antibiotic Resistance, But Impose Cuts Elsewhere
HIVMA Endorses the Equality Act
GLOBAL HEALTH
Science Speaks Covers UN Meeting on Ending AIDS
EDUCATION AND RESOURCES
IDWeek Mentorship Program
IDSA Foundation Offers Three Research Awards in 2016
HIVMA Medical Student Program Aims to Inspire Careers in HIV
Support IDSA Foundation Through CFC
ABIM Seeks Your Input on MOC Exams
New CDC and Mass General Resource Helps Travelers Stay Healthy
FROM THE PRESIDENT
Antimicrobial Resistance: Persistence Pays Off With This Strategic Priority
TOP STORIES
New IDSA Guideline on Diagnosis and Treatment of Aspergillosis
OPAT Handbook Now Available in Interactive, Digital Format
Donít Miss the Meeting Everyone Will be Talking About at IDWeek 2016!
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.